spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Leucovorin 

 HSMN NewsFeed - 9 Jun 2023
Astellas Submits New Drug Application for Zolbetuximab in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2021
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2017
Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Oct 2016
Shire Granted EU Marketing Authorization of Onivyde(R), in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2016
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2016
SIRFLOX Study Published in Journal of Clinical Oncology
Devices Interventional Radiology Oncology
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2015
Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) from U.S. Food and Drug Administration (FDA) for EVOMELA(TM) (melphalan) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 May 2014
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2014
Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2014
Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jul 2013
Spectrum Pharmaceuticals Acquires Talon Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Jun 2013
Spectrum Pharmaceuticals Further Strengthens Management; Announces Appointment of Kurt Gustafson as Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2013
Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Jan 2013
Spectrum Pharmaceuticals Acquires Rights for Apaziquone in the U.S., Europe and Other Territories from Allergan; Expects to File New Drug Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2012
Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence in U.S. Market
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2012
Spectrum Pharmaceuticals Appoints Industry Veteran, Former Amgen Executive Joseph Turgeon, as Senior Vice President Sales & Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Sep 2012
Spectrum Pharmaceuticals Appoints Industry Veteran and Former Senior Amgen Executive, Ken Keller, as Executive Vice President, Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2012
Spectrum Pharmaceuticals Launches a Broad-based FUSILEV(R) Marketing Campaign; Increases Sales Force Footprint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2012
Spectrum Pharmaceuticals Strengthens Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2011
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2010
Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2010
Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2010
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review for Advanced Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Aug 2009
Hospira Launches Generic Oxaliplatin Injection
Biopharmaceuticals Generics Oncology FDA
 HSMN NewsFeed - 1 Jun 2009
Randomized Controlled Trial of Radioactive Resin Microspheres Demonstrates Significant Delay in Progression of Disease in Patients with Colorectal Cancer Liver Metastases who have Exhausted Chemotherapy
Biopharmaceuticals Oncology Gastroenterology
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2009
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2008
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2008
Spectrum Pharmaceuticals Launches FUSILEV(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 May 2008
Spectrum Pharmaceuticals Receives $20 Million Cash Payment from Par Pharmaceutical for Sumatriptan Injection
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2008
Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2008
APP Pharmaceuticals Receives Final Approval for Irinotecan Hydrochloride Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 2 Nov 2007
ADVENTRX Provides Update on Cofactor(R) Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Oct 2007
APP Receives Tentative FDA Approval for Irinotecan Hydrochloride Injection, 20 mg/mL Packaged in 2 mL and 5 mL Single-Use Vials
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 25 Sep 2007
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Pro-Pharmaceuticals Names Theodore Zucconi, Ph.D., President; Nominated to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2007
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2007
Pro-Pharmaceuticals Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 28 Jun 2007
Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Health Canada approves new chemotherapy treatment for patients with metastatic colorectal cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jun 2007
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 4 Jun 2007
The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Pro-Pharmaceuticals Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
Pro-Pharmaceuticals Plans to Submit a New Drug Application for DAVANAT(R), as a Functional Excipient, with 5-FU to Treat Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Pro-Pharmaceuticals Receives Letter from the FDA for New Drug Application for DAVANAT(R)/ 5-FU
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2007
Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients with DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Mar 2007
Roche Submits Application to the FDA for use of XELOX (Xeloda(R) plus oxaliplatin) With or Without Avastin(R) for the Treatment of Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Feb 2007
Pro-Pharmaceuticals Submits Orphan Drug Status Application to European Medicines Agency Co-administration of DAVANAT(R) with 5-FU to Treat Cholangiocarcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2007
Pro-Pharmaceuticals Meeting Scheduled with the FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Pro-Pharmaceuticals' Begins Process of New Drug Application Submission with the FDA for Co-administration of DAVANAT(R) with 5-FU in Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Colon Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2007
Results Show XELOX (Xeloda(R) plus oxaliplatin) Provides Equivalent Overall Patient Survival Compared to FOLFOX in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Dec 2006
ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Xeloda(R) Combination Meets Primary Endpoint in International Phase III Advanced Colorectal Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
XELOX (Xeloda(R) + oxaliplatin) Shown to be as Effective as Current Standard in the Treatment of Advanced Colorectal Cancer for Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Jun 2006
ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2006
ADVENTRX Initiates CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jun 2006
Data Safety Monitoring Board Recommends Continuation of ADVENTRX Phase IIb Clinical Trial for CoFactor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 85

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 85 additional stories matching:
Leucovorin
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!